Zugl.: Berlin, Techn. Universiẗat, Diss., 2009.

Diss. Nr. 2362 Wirtschaftswiss. St. Gallen. / Literaturverz.

Diss. Wirtsch.-wiss. St. Gallen, 2005 ; Nr. 3102. / R& D: Research & development.

Master-Arbeit Univ. St. Gallen, 2007.

St. Gallen, Univ., Diss.

Using data from the biopharmaceutical industry, this study analyzes the relationship between internal and external exploration (exploitation) and the moderating role of firm characteristics. We argue that the characteristics of a firm - in particular a firm's vertical scope - are an important but so far overlooked contingency factor determining the relationship between internal and external exploration (exploitation). Our findings indicate that differences in vertical scope result in alternative combinations of internal and external exploration. While specialized firms tend to focus either on exploration or exploitation both within the firm as well as with their alliance portfolio, vertically integrated firms prefer to balance exploration and exploitation across firm boundaries. (authors' abstract) / Series: Working Papers / Institute for Strategic Management

Univ., Diss.--Bonn, 2006. / Literaturverz. S. 239 - 249.

Zugl.: Münster (Westf.), Universiẗat, Diss., 2008.

Vorliegender Leitfaden ist eines der Ergebnisse des Forschungsprojekts „Open Innovation in Life Sciences“ (OIL), das von Mai 2008 bis April 2011 an der Universität Potsdam durchgeführt wurde. Er nimmt für sich in Anspruch, gerade Innovationsmanager in kleinen und mittleren Unternehmen (KMU) der Pharmaindustrie bei der Einführung des Open Innovation Managements zu unterstützen. Zielsetzung des Forschungsprojekts war es, (1) die Chancen und Risiken von Open Innovation unter besonderer Berücksichtigung der Anforderungen von Pharma-KMU zu analysieren und (2) daraus abgeleitet ein Konzept zur Implementierung von Open Innovation bei Pharma-KMU zu entwickeln. Der Ausgangspunkt des Projektes war die Erkenntnis, dass die Life Sciences-Branche im Allgemeinen und die Pharmaindustrie im Besonderen durch eine steigende Komplexität der Innovationsprozesse und eine zunehmende Tendenz zu Kooperationen gekennzeichnet ist. Vor diesem Hintergrund eröffnet gerade der Open Innovation-Ansatz für die Pharmabranche neue Gestaltungs- und damit Wachstumsmöglichkeiten. Open Innovation – definiert als die planvolle Öffnung der Innovationsprozesse und die strategische Einbindung des Unternehmensumfelds – wird dabei als zentraler Erfolgsfaktor für die Innovationsfähigkeit beschrieben. / The job title of innovation manager is a comparatively new phenomenon in innovation management. The field of responsibility spans the entire innovation process, from fundamental research, development and production, until the market launch. The competencies include technology, product, service and market orientation, and an innovation manager should have skills in both the strategic as well as the operational sphere. They direct the innovation process, cultivate both internal and external contacts and organise the communication of all persons involved. It is self-evident that these tasks – particularly in the pharmaceutical industry with its complex and long-term processes – present a considerable challenge for every innovation manager. With this in view, the following guidelines are directed primarily at innovation managers in medium sized pharmaceutical companies. The guidelines convey the knowledge and tools that enable the development of market and customer oriented products and services in the pharmaceutical industry from the very start. By means of images and descriptions it demonstrates which steps should be followed from idea generation, to project realization, until the market launch. The centerpiece is formed by the division of the innovation process into manageable, clearly defined phases, specifically tailored for the pharmaceutical industry. The guidelines particularly focus on the question of how customers, suppliers, competitors, etc. can be integrated into this process. This approach – termed open innovation in innovation management – when applied as a deliberate strategy, has the potential to reduce the costs of development and to raise the speed of passage of projects.

Univ., Diss.--Hohenheim, 2004.